Infection with Helicobacter pylori is a risk factor for the development of gastric cancer.
However, it is not known whether eradication therapy can prevent the development of gastric cancer in persons in whom the cancer is not yet established.
Dr Mizuno and colleagues from Japan investigated whether the eradication of H. pylori in patients with peptic ulcer disease reduces the likelihood of their developing gastric cancer.
The investigative team conducted prospective posteradication evaluations in 1342 consecutive patients.
| Gastric cancer developed in 8 of 944 patients cured of H. pylori infection|
|American Journal of Gastroenterology|
The patients included 1191 men and 151 women with a mean age of 50 years and with peptic ulcer diseases who had received H. pylori eradication therapy.
The researchers performed, endoscopy and a urea breath test yearly after eradication was confirmed.
The researchers reported that a total of 1120 patients completed more than 1 year follow-up and were followed for up to 9 years.
The team noted that gastric cancer developed in 8 of 944 patients cured of infection and 4 of 176 who had persistent infection.
The research team also observed that all the gastric cancer developed in patients with gastric ulcer, but none in patients with duodenal ulcer.
In addition, the investigators found that in patients with gastric ulcer, persistent infection was identified as a significant factor for the risk of developing gastric cancer.
Dr Mizuno and team concluded, “H. pylori eradication may reduce the risk of developing gastric cancer in patients with gastric ulcer.”
"Large-scale studies in additional populations of this important international public-health issue are warranted.”